Letter to the Editor: Standard Chemoradiotherapy with Concurrent and Adjuvant Camrelizumab in Patients with High Risk Nasopharyngeal Carcinoma: Multicentre, Randomised, Open Label, Phase 3 Trial

Why It Matters

The findings highlight a promising but unproven immunotherapy strategy for a cancer with limited curative options, underscoring the need for robust OS data and practical implementation evidence before widespread adoption.

Key Takeaways

• Camrelizumab improved PFS but did not achieve statistically significant OS benefit
• Only 62% of patients completed the full 17‑cycle adjuvant regimen
• Trial lacked biomarker analysis to pinpoint patients most likely to respond
• Control arm did not isolate PD‑1 blockade effect from maintenance therapy
• Long‑term safety and cost‑effectiveness of intensive schedule remain unknown

Pulse Analysis

Nasopharyngeal carcinoma (NPC) remains a therapeutic challenge, especially in high‑risk patients where locoregional control is paramount. Over the past decade, PD‑1 inhibitors such as camrelizumab have entered clinical trials, aiming to boost the immune response after definitive chemoradiotherapy. The recent multicentre phase‑3 study adds a concurrent and prolonged adjuvant immunotherapy component, positioning it as one of the most intensive regimens tested in NPC to date. While the trial demonstrates a clear progression‑free survival advantage, the lack of a statistically significant overall‑survival signal raises questions about the true clinical value of extending treatment beyond the conventional window.

Beyond efficacy metrics, the trial’s design surfaces practical concerns. Seventeen adjuvant cycles translate into a 19‑cycle schedule when combined with concurrent dosing, yet only roughly two‑thirds of participants completed the full course, partly due to pandemic‑related disruptions. This adherence gap suggests that the regimen may be difficult to implement outside controlled trial settings. Moreover, the control arm—standard chemoradiotherapy alone—does not differentiate the specific contribution of PD‑1 blockade from other maintenance strategies, such as metronomic capecitabine, which have shown benefit in similar populations. The absence of biomarker stratification, like EBV DNA kinetics or PD‑L1 expression, further limits clinicians’ ability to target therapy to those most likely to respond.

For oncologists and health‑system decision‑makers, the study signals both opportunity and caution. The PFS improvement hints at a potential new therapeutic avenue, but without confirmed overall‑survival gains, cost‑effectiveness data, and safety profiling over longer horizons, the regimen cannot be universally endorsed. Future research should focus on head‑to‑head comparisons of immunotherapy versus other maintenance options, shorter adjuvant durations, and the integration of predictive biomarkers to personalize treatment. Until such evidence emerges, camrelizumab‑enhanced chemoradiotherapy remains an investigational approach rather than a definitive standard for high‑risk NPC.